Revive Therapeutics Ltd (RVVTF)

[Fress]

Anything under .50 is a gift.


Multi Dollars in the coming weeks and months.


$10:00-$20.00 on Approval in 2020.


Q3 Patient enrollment / dosing of Phase 3 study of Bucillamine in the treatment of COVID-19.

Q4 Initial results from Phase 3 clinical study of Bucillamine in the treatment of COVID-19.



ASIA Trials
https://thefly.com/landingPageNews.php?id=3069290&headline=RVVTF-Revive-Therapeutics-engages-Novotech-as-AsiaPacific-CRO-for-bucillamine

CANDIAN Trials:
https://www.globenewswire.com/news-release/2020/06/03/2043083/0/en/Revive-Therapeutics-Announces-Filing-of-a-Pre-CTA-Meeting-Request-with-Health-Canada-and-Update-on-U-S-FDA-IND-Filing-and-Phase-3-Clinical-Trial-Design-for-Bucillamine-in-the-Treat.html

USA Trials
https://www.globenewswire.com/news-release/2020/04/23/2020948/0/en/Revive-Therapeutics-Announces-U-S-FDA-Recommendation-to-Proceed-Directly-Into-A-Phase-3-Confirmatory-Clinical-Trial.html



$RVVTF